Drug Profile
Research programme: CD40-targeted therapeutics - PYC Therapeutics
Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Phylogica
- Developer PYC Therapeutics
- Class Peptides
- Mechanism of Action CD40 ligand modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Australia (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Australia (Parenteral)
- 24 Feb 2011 The programme is in active development